Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +54.73%
#2 Pons Pons +49.77%
#3 StonkBroker StonkBroker +37.83%
#4 PondCoin PondCoin +37.35%
#5 TENDIES TENDIES +36.53%
#6 Magma Finance Magma Finance +34.48%
#7 Ocean Protocol Ocean Protocol +33.58%
#8 Official Trump Official Trump +27.66%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#10 Ore Ore +26.90%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
MegaPro Biomedical Co., Ltd MegaPro Biomedical Co., Ltd

MegaPro Biomedical Co., Ltd

6827
Rank in Stocks #28596
MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily... MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily focused on pioneering nanodrugs. Its innovative development pipeline includes MPB-1523, an IOP injection currently in Phase II clinical evaluation for addressing hepatocellular carcinoma. Simultaneously, MPB-1514, an iron injection, is also undergoing Phase II clinical trials, targeting iron deficiency anemia. Furthermore, the firm is advancing MPB-1734, an anti-cancer pharmaceutical, which is in preclinical assessment for the treatment of malignant tumors. Established in 2014, this company is headquartered in Zhubei, Taiwan.
Share Price
$0.32276013
Last synced: 2026-08-17
Market Cap
$25.60M
Change (1 day)
0.00%
Change (1 year)
-38.97%
Country
TW
Trade MegaPro Biomedical Co., Ltd (6827)

Category

Healthcare
Revenue for MegaPro Biomedical Co., Ltd (6827)
Revenue in Aug 2026 TTM: 0
According to MegaPro Biomedical Co., Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MegaPro Biomedical Co., Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH